Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

I'm glad that they did not can Aim2Cerv program. The issue is how they are going to stretch the cash they have to fund all the current and future trials? The math simply does not work unless they get a big cash infusion soon. They can no longer rely on raising cash via secondary -- it will just kill the company. The cash balance is too low, and Bolivar cannot carry two. Maybe, he addresses the cash issue during the call. I am concerned no payment from Amgen is mentioned.